 Life Science Investor Mandates (Mar. 3 - Mar. 9) |
| |
|
Seeks Therapeutics, Cancer Diagnostics & PMA Devices with Clinical Data
|
Seeks Medical Devices, Diagnostics and Healthcare IT
|
|
Seeks Devices and Diagnostics across Northeast
|
|
|
By Bill Brah, Founder and Director, UMass VDC
 54% of the life science companies (including MIT spinout SQZ Biotech) launched at the VDC were founded by foreign-born entrepreneurs that came to Massachusetts for graduate study and remained to launch a company. The Massachusetts Global Entrepreneur-in-Residence Program has increased their odds of getting a visa from less than 50% to 100%!
The Venture Development Center, more commonly referred to as the "VDC" at University of Massachusetts in Boston, is an experienced community guiding startup companies from vision to launch, no strings attached. Ninety-five entrepreneurs, both from life science and technology, are currently in residence. About one-third are from UMass...
|
 |
|
 Early stage therapeutics companies have a long road ahead to reach the marketplace, and will require significant investment along their way. The level of risk involved at this stage deters some investors, and much has been written about the pull-back of many venture capital firms from this phase of investment. At RESI, a panel of 5 investors who are highly experienced in investing in early stage therapeutic development will discuss how they pick winning scientfic teams and support their portfolio companies through the challenges of the development process.
Moderated by Lisa Rhoads, Managing Director, Easton Capital, the panel will feature: - Thorsten Melcher, Senior Director, New Ventures & Partnerships, Johnson & Johnson Innovation
- Leo Linbeck III, Chairman & Founder, Fannin Innovation Studio
- John Westwick, Entrepreneur in Residence, Mercury Fund
- Michael Lang, Chief Product Development Officer, Cancer Prevention and Research Institute of Texas (CPRIT)
|
|
|
Venture philanthropy organizations provide more than just financing. Often times, these investors can provide a network of experts, patients, and resources in their niche space. Here in Next Phase, LSN has previously covered trends in venture philanthropy investment and advice in how to approach venture philanthropy investors.
LSN is pleased to announce a panel of five investors in the venture philanthropy space for RESI@TMCx on April 11th. Moderated by Jit Patel, VP of Research and Business Development of Juvenile Diabetes Research Foundation (JDRF), the panel will be joined by:
- Debra Miller, Founder & CEO, CureDuchenne
- John Parker, Trustee & Managing Director (CH Innovations), Charles H. Hood Foundation
- Grace Pavlath, Senior VP & Scientific Program Director, MDA Venture Philanthropy
- Rick Jones, Director, Broadview Ventures
|
|
|
